Plain-English translation of NCT07363460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called HSK39297 to see if it can safely treat lupus nephritis—a condition where lupus damages the kidneys. About 105 patients will receive either the medication at one of two doses, or a placebo (a pill with no medicine), and researchers will track how well the treatment works and whether it's safe.
Lupus nephritis is a serious complication that can lead to kidney failure if not treated well. While doctors have some treatments available, this medication could offer patients another option to help control kidney damage and reduce protein loss in the urine.
You likely qualify if…
You likely don't qualify if…
You will take a pill by mouth once each day for 52 weeks (one year). You'll be randomly assigned to receive either the medication at a lower dose, the medication at a higher dose, or a placebo—and neither you nor the study team will know which one you're taking. Throughout the year, you'll have regular visits for blood tests, urine tests, and check-ups to monitor how your kidneys are responding and whether you're experiencing any side effects.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Enrollment target
~105 participants
Started
November 2025
Primary completion
November 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
fangqiong Li
Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.